Cochrane Collaboration Issue 11, 2016…

from Health Economics and Decision Science Blog @ ScHARR at on November 29, 2016 at 11:30PM

….is complete.  The website lists protocols and methodology papers as well, but we’ll just flag up the notable reviews; these being……

  • Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
  • Adjuvant platinum‐based chemotherapy for early stage cervical cancer
  • Gene therapy for sickle cell disease
  • Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
  • Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease
  • Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)